PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.28%
Net income growth under 50% of AGEN's 135.69%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
720.76%
D&A growth well above AGEN's 6.26%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
100.00%
Some yoy growth while AGEN is negative at -100.00%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-18.24%
Both cut yoy SBC, with AGEN at -4.52%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-114.66%
Negative yoy working capital usage while AGEN is 734.80%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-121.66%
Both negative yoy AP, with AGEN at -134.61%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
139.41%
Lower 'other working capital' growth vs. AGEN's 18992.04%. David Dodd would see fewer unexpected short-term demands on cash.
-139.67%
Negative yoy while AGEN is 8.37%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-28.06%
Negative yoy CFO while AGEN is 313.86%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-383.87%
Both yoy lines negative, with AGEN at -149.53%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-383.87%
Both yoy lines negative, with AGEN at -149.53%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-88.00%
Negative yoy issuance while AGEN is 724.50%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.